Rontalizumab

Rontalizumab is a humanized monoclonal antibody designed for the treatment of rheumatoid arthritis. It was developed by Genentech, a member of the Roche Group. Rontalizumab targets and inhibits the interferon alpha (IFN-α), a protein that plays a key role in the inflammatory process of rheumatoid arthritis.

Development and Clinical Trials

Rontalizumab was developed by Genentech, a biotechnology company that specializes in the research and development of medicines for serious diseases. The drug was designed to target and inhibit the activity of IFN-α, a protein that is involved in the inflammatory process of rheumatoid arthritis.

In clinical trials, rontalizumab was found to be well-tolerated and showed potential efficacy in reducing the signs and symptoms of rheumatoid arthritis. However, the drug did not meet the primary endpoint in a Phase II study, which led to the discontinuation of its development.

Mechanism of Action

Rontalizumab works by binding to IFN-α, a protein that plays a crucial role in the inflammatory process of rheumatoid arthritis. By inhibiting the activity of this protein, rontalizumab can potentially reduce the inflammation and pain associated with this condition.

Potential Side Effects

As with any medication, rontalizumab may cause side effects. In clinical trials, the most common side effects reported were infections, including upper respiratory tract infections and urinary tract infections. Other potential side effects include injection site reactions, fatigue, and nausea.

See Also

• Monoclonal antibodies
• Rheumatoid arthritis
• Interferon alpha
• Genentech
• Roche Group